Investors in Anthem Biosciences Limited (NSE:ANTHEM) had a good week, as its shares rose 2.5% to close at ₹778 following the release of its quarterly results. Results look mixed - while revenue fell marginally short of analyst estimates at ₹4.2b, statutory earnings were in line with expectations, at ₹10.43 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the most recent consensus for Anthem Biosciences from seven analysts is for revenues of ₹25.6b in 2027. If met, it would imply a sizeable 28% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to soar 26% to ₹12.86. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹25.7b and earnings per share (EPS) of ₹12.95 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Anthem Biosciences
It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹884. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Anthem Biosciences, with the most bullish analyst valuing it at ₹941 and the most bearish at ₹830 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Anthem Biosciences is an easy business to forecast or the the analysts are all using similar assumptions.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that Anthem Biosciences is forecast to grow faster in the future than it has in the past, with revenues expected to display 39% annualised growth until the end of 2027. If achieved, this would be a much better result than the 2.2% annual decline over the past year. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 18% annually. So it looks like Anthem Biosciences is expected to grow faster than its competitors, at least for a while.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Anthem Biosciences going out to 2029, and you can see them free on our platform here..
You can also see our analysis of Anthem Biosciences' Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.